Combining Cagrilintide & Semaglutide for Health & Longevity

Created on 10/31/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Cagrilintide & semaglutide is a not-yet-approved medication pairing two long-acting copies of natural appetite hormones in one weekly injection, used for weight loss. It produces some of the largest weight losses of any medicine, plus better blood sugar and lower blood pressure. Heart, kidney and survival benefits are shown only for semaglutide alone, and lean, healthy adults are unstudied. Digestive side effects are common, and weight returns when treatment stops. (Full Review)

Protocol

Standard combination regimen
2.4 mg + 2.4 mg weekly
Cagrilintide plus semaglutide (1:1 ratio) in one fixed-dose injection; filed with the FDA, not approved in the U.S.
Titration
Every 4 weeks over 16 weeks
Both agents escalated together, typically 0.25, 0.5, 1.0, 1.7, then 2.4 mg each
Time of day
Same weekday each week
Any time, with or without food
Time to effect
Weight loss
Continues to about 68 weeks
Appetite falls within days; weight loss accrues through the 16-week escalation
Blood sugar (HbA1c)
Within months
HbA1c lowering, tested as the combination in type 2 diabetes
Blood pressure
Within months
Systolic and diastolic falls versus placebo

Benefits

Contraindications
  • People with a personal or family history of medullary thyroid carcinoma or MEN 2 (contraindicated)
  • People with a prior serious hypersensitivity reaction (anaphylaxis, angioedema) to semaglutide or its inactive ingredients (contraindicated)
  • Pregnancy, or planned pregnancy within 2 months (discontinue at least 2 months before)
  • Severe gastroparesis (not recommended)
  • Confirmed NAION during treatment (stop semaglutide)
  • People with active or past eating disorders such as anorexia nervosa (inferred; no human data)
Key Interactions
  • Insulin and sulfonylureas (glimepiride, glipizide): higher risk of low blood sugar, including severe episodes
  • Levothyroxine and other narrow-therapeutic-index oral drugs (phenytoin, cyclosporine): may alter absorption
  • Blood-pressure drugs (ACE inhibitors, ARBs, thiazide diuretics): low blood pressure more frequent; additive lowering may cause dizziness
  • Other GLP-1 receptor agonists or semaglutide products (liraglutide, tirzepatide, compounded semaglutide): avoid combined use
  • General anesthesia and deep sedation: retained stomach contents raise the risk of inhaling them
Theoretical (inferred from mechanism)
  • NSAIDs (ibuprofen, naproxen) and diuretics (furosemide, hydrochlorothiazide): additive kidney stress during vomiting or diarrhea
  • Over-the-counter drugs that slow the gut (loperamide, diphenhydramine): may worsen constipation
  • Glucose-lowering supplements (berberine, chromium picolinate): additive glucose lowering, relevant mainly with insulin or sulfonylureas
  • Blood-pressure-lowering supplements (beetroot nitrate, aged garlic extract): additive blood-pressure lowering and dizziness
  • Fiber supplements (psyllium, glucomannan): may worsen bloating and nausea
  • Pramlintide: more nausea and low blood sugar; avoid
  • Prolonged fasting or very-low-calorie diets: may accelerate muscle loss and gallstone formation

Risk & Side Effects

  • High: Gastrointestinal adverse events
  • Medium: Altered skin sensations; gallbladder disease; fatigue; injection-site reactions; smaller cholesterol improvement than semaglutide alone; optic nerve stroke; faster heart rate; low blood pressure and fainting; retained stomach contents during anesthesia; hypoglycemia; hair loss; appendicitis; kidney stones; headache and dizziness
  • Low: Diabetic eye disease worsening; acute pancreatitis; thyroid C-cell tumors; lean mass loss; hip and pelvic fractures; suicidal thoughts and mood changes; serious allergic reactions
  • Speculative: Renin-angiotensin system activation; bone effects of calcitonin-receptor activation

Monitoring

Marker Target Why
Body weight and waist circumference No established target; track percent change from own baseline Expected to change; trial endpoint
Blood pressure Not specified in the ER Expected to improve
HbA1c 4.0–5.6% Expected to change
Fasting glucose 70–99 mg/dL Expected to change; safety if on insulin or sulfonylureas
LDL cholesterol No established target; track change from own baseline Expected to change
Creatinine with eGFR Creatinine about 0.6–1.3 mg/dL Safety check
ALT About 7–56 U/L Expected to change (fatty liver); safety
GGT Not specified in the ER Paired with ALT; liver or bile-duct stress
Lipase Within laboratory reference range Safety check, only with persistent abdominal pain
TSH About 0.4–4.0 mIU/L Safety check if on levothyroxine
Lean mass by DXA No established target; track change from own baseline Expected to change
Resting heart rate 60–100 beats per minute Safety check

Cadence: Baseline before starting (dilated eye exam for those with diabetes; DXA scan); weight, blood pressure, heart rate and symptoms every 4 weeks during the 16-week escalation; labs at 3 months; then every 6–12 months once the maintenance dose is stable; repeat body-composition scan at 6–12 months

Qualitative Assessment

  • Appetite, cravings and intrusive thoughts about food
  • Gastrointestinal tolerance (nausea, constipation, reflux)
  • Energy levels and fatigue
  • Strength, stamina and physical function
  • Mood and motivation
  • Any sudden change in vision